Prospective clinical study of the association between plasma level of free IGF-1 and myometrial invasion in patients with endometrial adenocarcinoma;Badanie prospektywne zależności pomiędzy poziomem wolnego insulinopodobnego czynnika wzrostu (IGF-1) w surowicy krwi a zaawansowaniem nowotworu u pacjentek z rakiem endometrium

Ginekologia Polska

Volumn 81, Issue 7, 2010, Pages 501-505

  Ali, Baloglu ^a   Incim, Bezircioglu ^a   Burcu, Cetinkaya ^a   Levent, Hicyilmaz ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Endometrial carcinoma; Insulin like growth factor 1; Myometrial invasion

Indexed keywords

ESTRADIOL; SOMATOMEDIN C;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MYOMETRIUM; PATHOLOGY; POLAND; PROGNOSIS; PROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLAND; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 77958177749     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Parkin D, Bray F, Ferlay J, [et al.]. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55, 74-108.
2. Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. APMIS. 2009, 117, 693-707.
3. Sorosky J. Endometrial cancer. Obstet Gynecol. 2008, 111, 436-447.
4. Gunter M, Hoover D, Yu H, [et al.]. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17, 921-929.
5. Juul A, Holm K, Kastrup K, [et al.]. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab. 1997, 82, 2497-502.
6. Rosen C, Pollak M. Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab. 1999, 10, 136-141.
7. Liu H, He Z, Mele C, [et al.]. Hormonal regulation of expression of messenger RNA encoding insulin-like growth factor binding proteins in human endometrial stromal cells cultured in vitro. Mol Hum Reprod. 1997, 3, 21-26.
8. Pavelic J, Matijevic T, Knezevic J. Biological and physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res. 2007, 25, 511-522.
9. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, [et al.]. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004, 108, 262-268.
10. Kaklamani V, Linos A, Kaklamani E, [et al.]. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol. 1999, 17, 813-817.
11. Missmer S, Spiegelman D, Bertone-Johnson E, [et al.]. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-to 3-year period. Cancer Epidemiol Biomarkers Prev. 2006, 15, 972-978.
12. Bermont L, Lamielle F, Fauconnet S, [et al.]. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int J Cancer. 2000, 85, 117-123.
13. Frystyk J, Skjaerbaek C, Vestbo E, [et al.]. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999, 15, 314-322.
14. Rutanen E, Stenman S Blum W, [et al.]. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab. 1993, 77, 199-204.
15. Petridou E, Koukoulomatis P, Alexe D, [et al.]. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology. 2003, 64, 341-345.
16. Weiderpass E, Brismar K, Bellocco R, [et al]. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer. 2003, 89, 1697-1704.
17. Lacey J Jr, Potischman N, Madigan M, [et al.]. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev. 2004, 13, 607-612.
18. Oh J, Wu W, Tortolero-Luna G, [et al.]. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13, 748-752.
19. Ayabe T, Tsutsumi O, Sakai H, [et al.]. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J. 1997, 44, 419-424.